Skip Navigation



JAC Advance Access published online on September 1, 2006

Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkl367
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
58/5/1082    most recent
dkl367v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Martínez, J. A.
Right arrow Articles by Mensa, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Martínez, J. A.
Right arrow Articles by Mensa, J.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org
Received June 7, 2006
Revised August 14, 2006
Accepted August 15, 2006

Brief report

Prior use of carbapenems may be a significant risk factor for extended-spectrum {beta}-lactamase-producing Escherichia coli or Klebsiella spp. in patients with bacteraemia

José A. Martínez 1 *, Josefa Aguilar 1, Manel Almela 2, Francesc Marco 2, Alex Soriano 1, Fina López 1, Valentina Balasso 1, Laura Pozo 1, and Josep Mensa 1

1 Department of Infectious Diseases, Hospital Clínic, IDIBAPS--University of Barcelona, Barcelona, Spain
2 Microbiology Laboratory, Hospital Clínic, IDIBAPS--University of Barcelona, Barcelona, Spain

* To whom correspondence should be addressed.
José A. Martínez, E-mail: jamarti{at}clinic.ub.es


   Abstract

Background: The increasing prevalence of extended-spectrum {beta}-lactamase (ESBL)-producing Enterobacteriaceae will probably trigger a rise in the use of carbapenems. The effect of these antibiotics on the risk of involvement of ESBL-producing organisms in serious infections is unclear.

Methods: Retrospective analysis of 2172 episodes of healthcare-associated bacteraemia diagnosed during a 3 year period in a teaching hospital. Putative risk factors included demographics, co-morbidities, previous isolation of an ESBL-producing organism and exposure to antibiotics. Univariate and multivariate analysis of the association of risk factors with ESBL-producing organisms was performed in the entire series of bacteraemic episodes and in those due to Escherichia coli or Klebsiella spp.

Results: In the entire series, prior isolation of an ESBL-producing organism [odds ratio (OR) 5.9 (3.02, 11.5)]; an ultimately/finally fatal co-morbidity [OR 2.8 (1.55, 4.95)]; renal transplantation [OR 4.3 (1.96, 9.63)]; a urinary source [OR 4.2 (2.22, 7.84)]; shock [OR 2.4 (1.35, 4.1)] and previous use of cephalosporins [OR 2.6 (1.54, 4.51)], carbapenems [OR 2.5 (1.24, 5.05)] and glycopeptides [OR 0.4 (0.13, 0.93)] were significantly associated with ESBL-producing E. coli or Klebsiella spp. by multivariate analysis. Prior isolation of an ESBL-producing organism, an ultimately/finally fatal co-morbidity, renal transplantation, and previous use of cephalosporins and carbapenems were also significant in the analysis restricted to episodes due to E. coli or Klebsiella spp.

Conclusions: In patients with healthcare-associated bacteraemia, prior use of carbapenems may be only second to cephalosporins as the most significant antibiotic exposure associated with the involvement of ESBL-producing organisms.

Keywords: imipenem; meropenem; hospital infections.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J Antimicrob ChemotherHome page
U. S. Jensen, L. Skjot-Rasmussen, S. S. Olsen, N. Frimodt-Moller, A. M. Hammerum, and on behalf of the DANRES Study Group
Consequences of increased antibacterial consumption and change in pattern of antibacterial use in Danish hospitals
J. Antimicrob. Chemother., April 1, 2009; 63(4): 812 - 815.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
P. M. Hawkey
The growing burden of antimicrobial resistance
J. Antimicrob. Chemother., September 1, 2008; 62(suppl_1): i1 - i9.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
N. Patel, L.-A. McNutt, and T. P. Lodise
Relationship between Various Definitions of Prior Antibiotic Exposure and Piperacillin-Tazobactam Resistance among Patients with Respiratory Tract Infections Caused by Pseudomonas aeruginosa
Antimicrob. Agents Chemother., August 1, 2008; 52(8): 2933 - 2936.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
E. Tacconelli, G. De Angelis, M. A. Cataldo, E. Pozzi, and R. Cauda
Does antibiotic exposure increase the risk of methicillin-resistant Staphylococcus aureus (MRSA) isolation? A systematic review and meta-analysis
J. Antimicrob. Chemother., January 1, 2008; 61(1): 26 - 38.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.